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1. Introduction
When initially designed, the stated objective of the
Women’s Health Initiative (WHI) was to evaluate the
impact of exogenous ‘‘oestrogens’’ and ‘‘progestins’’ on
cardiovascular health, osteoporosis and other condi-
tions associated with long-term deprivation of oestrogen
in menopausal women [1]. It remains to be determined
whether or not the completed studies have provided
deﬁnitive answers as to the impact of oestrogens and
progestins on the health of menopausal women. How-
ever, what has become clear in the interim, between the
initiation and completion of the study, is that the WHI
was not an evaluation of oestrogens and progestins per
se, but of a selected preparation of conjugated equine
oestrogens administered with or without medrox-
yprogesterone acetate. There is now overwhelming evi-
dence to suggest that diﬀerent oestrogens (and
progestins) are not recognised in the same way in all
cells. Thus, it is incorrect to assume that similar out-
comes, be they positive or negative, will be observed in
patients treated with diﬀerent estrogen (ET) or diﬀerent
estrogen/progestin combinations (HT) regimens other
than those studied in the WHI. This extremely im-
portant issue has not been considered adequately by
either the media or the medical community who have,
based on the ﬁndings of the WHI, condemned ET/HT in
general. It is worth noting that the Food and Drug
Administration (FDA) has given speciﬁc guidance on
this issue aﬃrming in an important decision in 1996 that
not all oestrogens are biologically equivalent. This di-
rection was provided following a scientiﬁc discussion
that concluded that a drug containing most of the high
aﬃnity oestrogens present in Premarin (conjugated
equine oestrogens) could not be approved as a generic of
the innovator drug as it was not biologically equivalent.
Speciﬁcally, they [the FDA] contended that since all
oestrogens were not functionally the same, it was not
possible to exclude any component of Premarin and
assume that biological equivalence could be assured. So
why then, given that the FDA has dissuaded the
grouping of oestrogens into a single functional category,
has the WHI had such an impact on all ET/HT thera-
pies? One obvious answer is that there has been a pro-
blem incorporating the recent advances in our
understanding of the molecular pharmacology of oes-
trogens and progestins into medical practice. Conse-
quently, one of the aims of this Review is to detail the
important advances in our understanding of oestrogen
and progesterone action that have occurred over the
past few years and how these advances should impact
upon modern menopausal medicine. This discussion will
also serve the purpose of outlining what the future holds
in this area of pharmaceutical exploration.
2. Oestrogen action
The ﬁrst oestrogen-containing medicines were in-
troduced into the clinic in 1947 for the treatment of the
climacteric symptoms associated with menopause. At
that time, the belief was that these hormones functioned
as cofactors for a transhydrogenase that was involved in
the generation of cellular nicotinamide adenine dinu-
cleotide phosphate (NADPH) [2]. However, the dis-
covery in the late 1950s by Jensen and colleagues of a
high aﬃnity oestrogen receptor (ER) in oestrogen
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responsive tissues and the subsequent demonstration by
O’Malley and coworkers that this functioned as a li-
gand-dependent transcription factor laid to rest the
transhydrogenase hypothesis [2–5]. It was these seminal
discoveries that marked the beginning of the modern era
of oestrogen (and progestin) pharmacology, a ﬁeld of
endeavour which in recent years has yielded a detailed,
though probably not complete, understanding of the
molecular determinants of ER pharmacology.
3. The oestrogen receptors are versatile regulators of
transcription and cell signalling
The biological actions of oestrogen are mediated by
two genetically distinct oestrogen receptors, ERa and
ERb, which share similar, though distinct, cellular ex-
pression proﬁles [6]. The second of these two receptors
(ERb), identiﬁed in 1996, has been shown to be func-
tionally distinct from the previously described ERa [7].
In the absence of hormone, these receptors are main-
tained in a quiescent state in target cell nuclei through
their association with heat-shock protein containing
inhibitory complexes. Upon binding an agonist, they
undergo a conformational change which facilitates their
displacement from this inhibitory complex [8–10]. This
results in the formation of ERa/ERb heterodimers in
cells expressing both receptor subtypes and homo-
dimeric complexes in cells expressing a single subtype
[9]. Whereas both receptor subtypes are capable of ac-
tivating transcription, ERa appears to be a more robust
activator than ERb [9]. Not surprisingly, therefore, in
cells where both receptors are expressed, it has been
shown that ERb moderates ER agonist activity [11].
Thus, the cellular response to oestrogens and anti-
oestrogens depends on the relative expression level of
both receptor subtypes in cells. That each ER subtype
plays a diﬀerent role in oestrogen action is supported by
(a) the distinct phenotypes observed in mice in which
either or both subtypes have been genetically disrupted
[12] and (b) the observation that ERb speciﬁc agonists
function as eﬀectively as prednisone in animal models of
inﬂammatory bowel disease and rheumatoid arthritis,
but do not manifest agonist activity in the reproductive
tract, bone or mammary gland [13].
When functioning as regulators of transcription, the
activated ERs can interact with target gene promoters
(a) directly by binding to speciﬁc, high aﬃnity Oestro-
gen Response Elements (EREs) within the regulatory
regions of target genes or (b) indirectly through protein–
protein interactions with transcription factors, like AP1
or SP1, which are prebound to target genes [14] (Fig. 1).
The DNA bound receptor is then capable of positively
or negatively regulating transcription. Of late, it has
become clear that ER can also function as a transcrip-
tional repressor by inhibiting the activity of transcrip-
tion factors such as NFjB [15]. This inhibition results as
a consequence of the physical interaction of the agonist-
bound ER with the p65 subunit of activated NFjB.
Although the precise mechanism by which this in-
hibitory activity is achieved has yet to be determined, it
appears that this function of ER explains the anti-in-
ﬂammatory actions of oestrogens observed in the brain
and cardiovascular system [16]. This inhibitory function
of ER may also play a role in mediating the anti-re-
sorbtive actions of oestrogens in bone, though the latter
conclusion remains controversial [17]. Finally, it has
been shown in vitro that oestrogens acting through ERa
or ERb can also participate in non-genomic, extra-nu-
clear signalling events [18]. Although the ﬁeld has not
reached consensus as to the mechanism or physiological
relevance of these latter activities, it is clear that there
are responses to oestrogens that occur in the cytoplasm,
or at the cell membrane of target cells, that do not im-
pact upon gene expression directly. Among these ob-
served responses, the activation of mitogen activated
protein kinase (MAPK), regulation of calcium tran-
sients and activation of endothelial nitric oxide synthase
(eNOS) in caveoli are the most intriguing [19–21]. The
activation of MAPK appears to occur as a result of cSrc
activation by a complex containing ligand-activated ER
and the coregulator MNAR (modulator of non-genomic
activity of oestrogen receptor). This pathway is of par-
ticular interest since MAPK itself can directly phos-
phorylate and potentiate ER transcriptional activity.
Thus, it is possible that MAPK activation and other
rapid non-genomic responses to oestrogens may provide
a priming mechanism by which the cell can amplify
hormonal responses. How ER, which is found pre-
dominantly in the nucleus, is relocalised to the cyto-
plasm or cell membrane to enable its participation in
non-genomic signalling events is currently unknown.
4. Oestrogen receptor pharmacology
The demonstration that ER can function as a ligand-
activated regulator of transcription allowed a simple
model of oestrogen and anti-oestrogen pharmacology to
emerge. In this model, agonists such as oestradiol, were
proposed to function as molecular switches that bound
and converted the receptor from an inactive to an active
form. When corrected for aﬃnity, therefore, all agonists
were considered to be qualitatively the same and, by
inference, receptor aﬃnity was believed to be the major
predictor of biological activity. It was also inferred by
this model that antagonists functioned by competitively
inhibiting agonist binding, freezing the receptor in an
inactive state [22]. It has now become clear that this
model does not adequately describe the actions of
known ER ligands. Of note, was the observation in
humans that the ‘‘anti-oestrogen’’ tamoxifen, while
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capable of opposing ER action in the breast, could
function as an estrogenic ligand in bone and in the
uterus [23–26]. These important studies led to the re-
classiﬁcation of tamoxifen as a Selective Oestrogen Re-
ceptor Modulator (SERM), a compound whose relative
agonist/antagonist activities can diﬀer between cells [27].
A second study that contributed signiﬁcantly to our
understanding of ER pharmacology was that which
demonstrated that receptor aﬃnity was a poor predictor
of biological activity [28,29]. Together these and other
compelling studies indicate that the same ER-ligand
complex is not recognized in the same manner in all cells
and that factors other than the receptor and its ligand
were important in regulating ER pharmacology. A re-
solution to this conundrum came in 1995 with the dis-
covery of the ﬁrst nuclear receptor co-factor, SRC-1
[30]. This protein interacts with agonist-activated ER
and potentiates its transcriptional activity. To date, a
large number of additional factors have been identiﬁed
which have been shown to interact with ER and mod-
ulate its activity in target cells [31]. Functionally, there
are two main classes of receptor interacting proteins,
coactivators which enhance, and corepressors that re-
press, transcription activity [32]. Coactivators function
by nucleating multiprotein complexes at target gene
promoters, which by catalysing histone acetylation fa-
cilitate chromatin decondensation and enhanced tran-
scription [33]. Corepressors function in reverse by
recruiting enzymes that enable histone deacetylation,
local condensation of chromatin and dampening of
transcriptional activity [33]. With regard to the ER
pharmacology, the most important ﬁnding was that the
functional activities of diﬀerent coactivators are not the
same and that the absolute and relative expression level
of these proteins can diﬀer between cells. Similarly, it
appears that cell-dependent diﬀerences in corepressor
expression levels and activity also exist [32]. Reﬂecting
these observations, it is now generally accepted that the
transcriptional activity of an ER-ligand complex in a
given cell depends on what coactivators and cor-
epressors are available [32–34]. However, a further em-
bellishment of this model was needed to explain how
chemically similar agonists can manifest diﬀerent activ-
ities within the same cell. We now know that the overall
structure of the ER-ligand complex is not the same in
the presence of diﬀerent ligands [10,35,36]. Speciﬁcally,
using a series of diﬀerent biochemical and structural
techniques, it has been shown that diﬀerent ligands in-
duce distinct structural alterations in ER [37–39]. In
addition to classical ligands, the sequence of the DNA to
which the ER is tethered is also a key modulator of
receptor structure [40]. The signiﬁcance of these diﬀer-
ences in conformational states was revealed when it was
demonstrated that conformation inﬂuences the recruit-
ment of cofactors to receptors [36,41,42]. Thus, the
cellular response to a given ligand is a reﬂection of the
conformation of the ER-ligand complex and its ability
to ﬁnd an appropriate cofactor. We now know that
additional complexity is engendered by cell signalling
pathways, which through their action on receptors di-
rectly or through cofactors can impact upon ER tran-
scriptional activity [43]. Indeed, so powerful are these
alternate pathways that they can lead to the activation
of the ER in the absence of a classical ligand [44,45].
Under normal physiological conditions, these alternate
pathways of activation are probably involved in the ﬁne-
tuning of ER action [46,47]. However, it is clear that in
certain pathological conditions they can dominate and
even obviate the need for a ligand [48].
In summary, the molecular pharmacology of ER is
extremely complex and is dictated by many factors. The
most important of which are (a) the expression level of
each of the two receptor subtypes in cells, (b) the impact
which ligands have on receptor structure, (c) the relative
and absolute expression level of cofactors, and (d) the
activity of signalling processes that can interface with
and modulate the activity of the component parts of the
ER signalling pathway. Within the context of this new
information, it is easy to appreciate why structurally
diﬀerent oestrogens can have dramatically diﬀerent
biological activities.
5. Progestin action
The essential elements of the progesterone signalling
pathway are similar to what has been described for ER.
The progesterone receptor exists in two forms in cells,
hPR-A and hPR-B, both derived from the same gene by
alternate use of two distinct promoters [49]. The B-form
of the receptor diﬀers from hPR-A by an amino-term-
inal extension of 164 amino acids [49]. However, this
small diﬀerence is suﬃcient to generate two molecules
with completely diﬀerent biological activities [50]. In
most environments, hPR-B functions as a ligand-de-
pendent activator of transcription whereas hPR-A dis-
plays minimal transcriptional activity on Progesterone
Response Element (PRE)-containing genes [50,51]. In-
stead, it appears from studies performed both in vitro
and in vivo, that hPR-A functions as a modulator of
hPR-B transcriptional activity [52]. This occurs as a
consequence of hPR-A’s ability to (a) form heterodimers
with hPR-B and dampen its activity and (b) function as
a transdominant inhibitor by interfering with the activ-
ities of coactivators associated with hPR-B [50,53]. The
latter mechanism has been shown to explain how pro-
gestins, acting through hPR-A, can inhibit agonist-ac-
tivated ER [54]. Speciﬁcally, hPR-A can interfere with
the ability of ER to assemble coactivator complexes on
target gene promoters. Because hPR-A and hPR-B are
mechanistically diﬀerent, it has been diﬃcult to come up
with a unifying model to describe PR pharmacology.
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Indeed, it has been more instructive to consider them as
‘‘diﬀerent’’ receptors that just happen to be regulated by
the same class of hormones. For instance, it has been
noted that any ligand that binds to hPR-A and facil-
itates its displacement from inhibitory heat-shock pro-
teins is capable of opposing ER signalling in cells where
both receptors are expressed [54]. For this reason, it is
not surprising that all known PR agonists and antago-
nists have been shown to be equally eﬀective at opposing
ER action in vitro and in vivo [54–56]. The actions of
progestins that are manifest in tissues such as the
mammary gland appear to require hPR-B [52]. In this
case, agonists can be distinguished from antagonists
although it remains to be determined if the currently
available progestins diﬀer in their ability to regulate
hPR-B function. The molecular pharmacology of PR
has not been as well-deﬁned as that for ER. Regardless,
we know enough to predict that, as with ER, it will be
possible to develop Selective Progesterone Receptor
Modulators (SPRMs), whose relative agonist/antagonist
activity will be manifest in a cell-selective manner. There
are now reports in the literature of new progestins which
display SPRM activity [57]. Conﬁrmation of this activity
in humans will change the face of HT removing some of
the liabilities believed to be associated with currently
prescribed progestins. To date, PR has been under-
explored as a drug discovery target. However, as the
speciﬁc regulators of progestin and antiprogestin phar-
macology are deﬁned, it is likely that this will change
and new improved pharmaceuticals will emerge.
6. The future of ER and PR pharmacology
In the aftermath of the WHI, there has been a tre-
mendous amount of discussion as to the future of ET/
HT and the role of ER and PR as therapeutic targets in
menopausal women. However, even a cursory con-
sideration of the mechanism of action of these two re-
ceptors reveals that the existing pharmaceuticals are
relatively primitive and that by using mechanism-based
approaches for new drug discovery, improved ther-
apeutics should emerge. Indeed, this has already started
to happen with the appearance of the SERM, raloxifene,
on the scene. This will soon be followed by bazedoxifene
and lazofoxifene, two third-generation SERMs [58–60].
Fig. 1. The oestrogen receptor (ER) signal transduction pathways. Upon binding an agonist, ER undergoes agonist-speciﬁc conformational changes
and forms dimeric complexes which then participate in several diﬀerent signalling pathways, depending on the cell type. Within the nucleus, the
receptor dimers recruit cofactors (coactivators or corepressors) and can interact with DNA directly through Oestrogen Response Elements (EREs) or
indirectly through prebound transcription factors, such as AP1, to aﬀect the transcription rate. Interestingly, although ER inhibits Nuclear Factor j
B (NFjB) activity, there is reason to believe that coactivators may be required. The non-genomic actions of ER occur in the cytoplasm or in caveoli
at the cell membrane. Data suggest that ER can activate mitogen-activated protein kinase (MAPK) with one possible route occurring through the
mediation of cSrc and MNAR (modular of non-genomic activity of oestrogen receptor) [42]. Finally ER, associated with the cell membrane, may be
responsible, e.g., for rapid oestrogen-induced calcium transients [63,64]. Whether the membrane receptors represent subtypes of ER diﬀerent than the
nuclear and cytoplasmic receptors remains to be determined [19,64]. For activated progesterone receptor (PR), the overall scheme of fates and
pathways is similar.
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Unfortunately, none of these SERMs can treat the va-
somotor symptoms associated with menopause [61].
However, although diﬃcult to understand from a me-
chanistic point of view, there is reason to believe that
combinations of a classical oestrogen with a SERM may
bring satisfactory relief from vasomotor symptoms with
a lower side-eﬀect proﬁle than currently approved
medicines [62]. Obviously, the next advance in this ﬁeld
will be the development of truly speciﬁc SERMs and
SPRMs. This, we believe, will be accomplished by de-
ﬁning the speciﬁc coactivators involved in a given pro-
cess and screening for compounds that enhance speciﬁc
ER-coactivator interaction.
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